Gufic BioSciences Share Price

Gufic Biosciences Limited is a small-cap pharmaceutical company engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and complex sterile injectable products. The company, incorporated in 1984, has a presence across regulated markets including the United States, Europe, and Australia. The Gufic Biosciences share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Gufic Biosciences stock price often mirrors shifts in API demand, regulatory outcomes from the USFDA, and investor views on the pharma sector’s growth prospects. Factors such as the pace of new product launches, competitive intensity from other generic drugmakers, regulatory pricing mechanisms, and government policies on healthcare influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Gufic Biosciences stock price movements. 

The Gufic Biosciences live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Gufic Biosciences live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Gufic Biosciences share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. 

Gufic Biosciences Limited Company Fundamentals 

A. Company Background

Gufic Biosciences Limited was incorporated in 1984. The company’s registered office is located in Mumbai, Maharashtra. Gufic Biosciences is a pharmaceutical company engaged in the business of manufacturing and marketing of APIs, generic pharmaceuticals, and complex sterile injectable products. The company has a presence in regulated markets such as the United States, Australia, Europe, Asia, and Africa. Gufic Biosciences operates manufacturing facilities which are audited by international regulatory agencies. The company is listed on the Bombay Stock Exchange (BSE) under the scrip code 509079 and on the National Stock Exchange (NSE) under the symbol GUFICBIO. The company has focused on building a pipeline of specialty products in the segments of hormones, peptides, and other niche therapeutic categories. Gufic Biosciences has continued to enhance its research and development capabilities to launch new products for global markets. 

B. Product Lines 

• Active Pharmaceutical Ingredients (APIs) for various therapeutic categories. 

• Generic pharmaceutical formulations in dosage forms including sterile injectables. 

• Hormones and peptides as specialised pharmaceutical ingredients. 

• Contract manufacturing services for global pharmaceutical companies. 

• Sterile injectable products for hospital and institutional use. 

• Complex generic formulations for regulated markets like the United States and Europe. 

• Pharmaceutical products for the domestic Indian market under the Gufic brand. 

C. Company Revenue Model 

• Primary revenue from sale of APIs and generic formulations to domestic and international customers. 

• Volume-driven revenue based on quantity of pharmaceutical products sold to various markets. 

• Pricing determined by regulatory approvals and competition, affecting overall revenue generation. 

• Revenue from contract development and manufacturing services for global pharmaceutical partners. 

• Expanding product portfolio in high-value niche segments contributing to revenue growth. 

• Focus on securing new drug master files and regulatory approvals to drive future sales. 

• Revenue from export markets, which include regulated territories like the United States and Europe. 

• Strategic partnerships with global pharmaceutical companies for product development and supply. 

• Seasonal variations in demand for certain therapeutic products affecting revenue patterns. 

• Government policy changes on drug pricing and healthcare spending influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Mumbai, Maharashtra, India. 

• Strong presence in the domestic Indian pharmaceutical market. 

• Export operations covering the United States, Australia, Europe, Asia, and Africa. 

• Focus on expanding into additional regulated markets for pharmaceutical products. 

• Operations primarily concentrated in the pharmaceutical manufacturing and distribution sector. 

• Strategic expansion through new product filings in international regulatory jurisdictions. 

E. Key Milestones 

• 1984: Incorporated as Gufic Biosciences Limited. 

• Began manufacturing of APIs and pharmaceutical formulations. 

• Received approvals from international regulatory bodies for manufacturing facilities. 

• Expanded product portfolio into sterile injectables and specialty products. 

• Listed on the Bombay Stock Exchange and the National Stock Exchange. 

F. Industry Perspective

Gufic Biosciences Limited operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2025 and is projected to reach USD 2.3 trillion by 2030, growing at a CAGR of 7.1% during this period. The generic drugs segment accounts for about 70-80% of total pharmaceutical volumes in major markets. In India, the pharmaceutical market is the world’s 3rd largest by volume and 14th by value. The Indian pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15-17%. India supplies over 50% of global demand for various vaccines and 40% of generic demand in the United States. Key drivers of demand include rising healthcare expenditure, increasing chronic disease prevalence, and government initiatives like the Production Linked Incentive (PLI) scheme for pharmaceuticals. Challenges include pricing regulations, intense competition, and regulatory compliance costs. 

Gufic Biosciences Limited Stock Market Presence: Listings & Index Representation 

Gufic Biosciences is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol GUFICBIO and on the Bombay Stock Exchange (BSE) with the scrip code 509079. Its listing on both exchanges ensures that the Gufic Biosciences share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The ISIN for the company is INE742B01025. The company forms part of several benchmark indices that represent broad market segments. Gufic Biosciences is included in indices such as the BSE SmallCap index, BSE Healthcare index, and S&P BSE AllCap index on the BSE. On the NSE, the company is a constituent of the Nifty Smallcap 250 index and the Nifty Microcap 250 index. Being represented in multiple indices enhances the visibility and liquidity of the Gufic Biosciences stock price, as index tracking funds often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross-sectional comparisons within India’s pharmaceutical landscape. 

Gufic Biosciences Limited Stock Performance and Share Price History 

The performance and share price history of Gufic Biosciences Limited are influenced by a complex mix of operational, regulatory, and macroeconomic factors. A primary driver is the fluctuation in regulatory approvals from agencies such as the USFDA, as any delay or complete response letter directly impacts the company’s revenue visibility, often leading to corrections in the Gufic Biosciences share price. Government policies regarding drug pricing, particularly the National Pharmaceutical Pricing Authority (NPPA) price caps on essential medicines, also play a critical role. For instance, when the government imposes price controls on key APIs, concerns about profitability emerge, putting pressure on the Gufic Biosciences stock price. Conversely, favourable policy moves, such as the PLI scheme for pharmaceuticals, have historically boosted investor sentiment. 

Another major factor is competition—from both large multinational pharmaceutical companies and smaller generic drugmakers—which can alter long-term growth projections and influence the Gufic Biosciences share price. The company’s product pipeline progress, driven by research and development investments and new drug master file filings, directly impacts revenue visibility. Quarterly financial results, especially net profit and sales volume figures, cause immediate swings in the Gufic Biosciences stock price. Additionally, broader market trends, developments in global healthcare spending, and currency fluctuations affecting export realizations contribute to volatility. Historically, the Gufic Biosciences share price has shown resilience during the COVID-19 pandemic but has also faced sharp declines during periods of regulatory uncertainty. Overall, the Gufic Biosciences stock price remains a barometer of both India’s pharmaceutical export capabilities and the regulatory stability affecting drugmakers. 

The 52-week high of the stock is largely dictated by sentiment shifts and external shocks. When the company receives new product approvals and launches products in regulated markets, the Gufic Biosciences share price tends to rally toward its 52-week high; conversely, any regulatory warning letter or delay in approval can drive the Gufic Biosciences share price down to a new low. The Gufic Biosciences share price also hits its peak when management announces strong export growth, while a sharp spike in input costs or pricing pressure pushes the Gufic Biosciences share price toward the yearly bottom. Broader market sell-offs, such as during economic slowdowns, often drag the Gufic Biosciences share price to multi-month lows, even if fundamentals are sound. Conversely, a strong USFDA approval spree can lift the Gufic Biosciences share price to a new 52-week high. Additionally, quarterly earnings misses or regulatory compliance concerns have historically pressured the Gufic Biosciences share price to test its lowest levels in a given year. 

The Gufic Biosciences share price has exhibited significant volatility over the past decade, shaped by the company’s focus on specialty pharmaceutical segments and broader industry cycles. The Gufic Biosciences share price recorded a negative total return of approximately 21.01% over the last 1 year and a negative return of 3.79% over the last 2 years, underperforming broader market indices and reflecting near-term headwinds including pricing pressure and regulatory delays. The Gufic Biosciences share price delivered a 20-year total return of 19.70%, demonstrating long-term wealth creation. The Gufic Biosciences share price reached a 52-week high of 408.00 and a 52-week low of 268.00, indicating a wide trading range. The Gufic Biosciences share price recorded a strong rally in 2021, delivering a substantial positive annual return of 102.99%, while the subsequent period has seen the Gufic Biosciences stock price moderate and correct from its peak levels. The Gufic Biosciences share price has shown a 1-month return of approximately -21.01% and a 6-month return that has been volatile. 

The Gufic Biosciences stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 3% growth in Q4 net profit, the Gufic Biosciences stock price showed a moderate reaction. The Gufic Biosciences stock price has shown a pattern of strong positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Gufic Biosciences stock price. Corporate developments, including strategic announcements such as the expansion of manufacturing capabilities and the filing of new drug master files, have also influenced short-term fluctuations in the Gufic Biosciences share price. The Gufic Biosciences share price has shown a 5-year total return of 110.35% according to some sources, reflecting the volatility in the stock. The Gufic Biosciences share price has shown a 10-year aggregate net profit of ₹453.01 crore, reflecting the company’s sustained profitability over the long term. The Gufic Biosciences share price reached its 52-week high of 408.00 before declining to its 52-week low of 268.00, reflecting the volatility inherent in the pharmaceutical space. The Gufic Biosciences share price has shown a year-to-date return of -15.30% as of April 2026, indicating continued pressure in the current fiscal year. Comprehending these patterns in the Gufic Biosciences share price is instrumental for investors seeking to contextualise long-term performance trends vis-à-vis short-term price dynamics, as the Gufic Biosciences stock price movements illustrate how industry fundamentals, regulatory cycles, and investor expectations converge in market pricing. 

The Gufic Biosciences share price has shown distinct seasonal patterns over the past decade. The best performing month historically was May 2021 with a positive return of 33.03%, while the worst month was March 2020 with a negative return of -24.94%. Historically, 58% of months have shown positive returns, with the average monthly return standing at +1.52% in up years. In terms of annual performance, the Gufic Biosciences share price delivered its strongest annual return of 138.25% in 2017, followed by a positive return of 102.99% in 2021. The stock recorded negative annual returns in 2018 (-26.27%), 2019 (-35.37%), 2022 (-4.69%), 2025 (-26.20%), and 2026 year-to-date (-15.30%). The Gufic Biosciences share price has demonstrated that the stock tends to perform better in periods of strong export demand and supportive regulatory outcomes, while underperforming during phases of regulatory uncertainty and intense generic competition. 

Gufic Biosciences Limited Investor Relevance and Role in Portfolio 

Gufic Biosciences holds a position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on the generics and specialty API segment. The company’s strong presence in API and formulation manufacturing aligns it with investment strategies that value pharmaceutical manufacturing capabilities and export growth. The Gufic Biosciences share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector-specific funds monitor regulatory approval indicators and product pipeline factors when evaluating allocation decisions. 

Institutional stakeholders play a role in Gufic Biosciences’s ownership profile, with notable long-term investment entities such as Motilal Oswal Financial Services Ltd, Life Insurance Corporation of India, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, SBI Mutual Fund, Mirae Asset Mutual Fund, and Tata Mutual Fund among key shareholders identified in institutional holdings data. Mutual fund holders of Gufic Biosciences encompass those that seek pharmaceutical exposure, including ICICI Prudential Mutual Fund – ICICI Prudential Multicap Fund, Nippon India Mutual Fund, and other fund houses. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks. 

Based on data, Gufic Biosciences exhibits varying levels of beta and volatility across different time horizons. Based on data, the long-term beta of Gufic Biosciences stands at 1.10, indicating that the stock is generally more volatile than the broader market over an extended period. Based on data, on a daily basis, the beta values are relatively stable, with a one-month daily range of 0.150 and a three-month daily range of 0.713, both suggesting near-neutral volatility in short-term trading. Based on data, moving to weekly observations, the one-year weekly beta is 0.739, showing slightly lower-than-market sensitivity, while the two-year weekly beta increases to 0.856, and the two-week two-year range stands at 0.925, indicating moderate fluctuations over medium-term cycles. Based on data, the monthly two-year beta is 1.30, highlighting moderate volatility and responsiveness to broader market trends in longer time frames. Based on data, supporting statistics such as mean values (ranging from 186.98 to 319.41) and standard deviations (from 2.10 to 13.25) further indicate variability in performance across periods. Overall, Gufic Biosciences demonstrates a mixed volatility profile—relatively stable in short-term daily measures but increasingly volatile in longer weekly and monthly horizons, making it sensitive to broader market shifts over time. 

The Gufic Biosciences share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Gufic Biosciences stock price’s beta reflects that the company’s pharmaceutical manufacturing nature and export focus may provide some stability, though the pharma sector remains sensitive to regulatory changes and drug price fluctuations. The Gufic Biosciences share price has historically moved on regulatory approval news. 

Gufic Biosciences Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Gufic Biosciences is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other active pharmaceutical ingredient and generic formulation manufacturers. As part of this industry, the company’s strategic positioning connects API production for export markets and formulation manufacturing for domestic and international use. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Ltd, Divi’s Laboratories Ltd, Torrent Pharmaceuticals Ltd, Aurobindo Pharma Ltd, Cipla Ltd, JB Chemicals & Pharmaceuticals Ltd, Cohance Lifesciences Ltd, and Alivus Life Sciences Ltd. Firms with parallels in either API scale or specialty product focus are often referenced when evaluating relative performance and operational positioning within the sector. 

In valuation terms, factors like the Gufic Biosciences P/E ratio have shown variations over different periods. The mean historical PE Ratio over the last ten years stands at 33.79, with the current 57.70 PE Ratio having changed significantly with respect to the historical average. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. The Gufic Biosciences P/E ratio decreased in 2024 and increased in 2021 and 2023. The trailing twelve months P/E ratio has been reported between 44x and 60x depending on the reporting period. 

Similarly, the Gufic Biosciences EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from API capacity expansion and new product filings supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from pricing pressure and raw material cost inflation have moderated EPS momentum. Gufic Biosciences earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. Gufic Biosciences market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market. 

Over years, the Gufic Biosciences market cap has followed a pattern of growth followed by moderation. From fiscal year 2016 onwards, the company’s market cap showed an increasing trend, reflecting strong investor confidence. The market cap increased from approximately ₹0.7 billion in 2016 to ₹3.5 billion in 2018, ₹5 billion in 2019, ₹8 billion in 2020, and reached a peak of ₹25 billion in 2021. Subsequently, from fiscal year 2022 through the most recent period, the market cap has shown a declining trend, contracting to ₹20 billion in 2023 and further to ₹29 billion in recent quarters while remaining highly volatile. This fluctuation mirrors the movement in the Gufic Biosciences share price and the broader performance of the pharmaceutical sector relative to broader market indices. 

The Gufic Biosciences earnings over the past ten years has been characterised by a period of growth followed by recent moderation. Net income showed a generally increasing trend, with reported net profit rising from ₹8 crore in 2015 to ₹12 crore in 2016, ₹15 crore in 2017, ₹20 crore in 2018, and reaching a peak of ₹86.14 crore in 2024. Subsequently, earnings have shown a moderating trend, with net profit decreasing to ₹69.93 crore in 2025, a -18.81% change from the ₹86.14 crore profit recorded in the previous year. This recent earnings moderation reflects the impact of demand normalisation, increased competitive intensity, and regulatory changes on the company’s profitability. 

The Gufic Biosciences EPS has shown an increasing trend over the majority of the past decade, indicating a strong financial track record. The diluted EPS growth rate has shown variation, with a growth rate of 116.67% in 2021, 93.51% in 2022, 42.66% in 2023, and a decline in subsequent periods. Over a ten-year period, the company demonstrated consistent improvement in EPS, with average earnings per share growth of 32.90% per year. In recent years, EPS showed a pattern of growth followed by a decline, with TTM EPS moderating from its peak levels. The highest 3-year average EPS growth rate was 24.80% per year, while the lowest was 8.90% per year. 

The Gufic Biosciences P/E ratio has shown fluctuations over the ten-year period. At the end of recent fiscal years, the P/E ratio varied, with 2015 at 5.71, 2016 at 7.48, 2017 at 10.4, 2018 at 12.2, and showing an increasing trend in subsequent years. The P/E ratio reached 33.0 in 2021, before moderating to 18.1 in 2022, 17.9 in 2023, 15.5 in 2024, and 16.8 in 2025. The mean historical P/E ratio over the last ten years is 21.35. The current P/E ratio stands at a certain level compared to the historical average, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Gufic Biosciences share price has been influenced by these valuation metrics. The Gufic Biosciences stock price continues to be evaluated in the context of its earnings potential and market position. 

Summary 

Gufic Biosciences is a pharmaceutical company listed on both the NSE and BSE, where the Gufic Biosciences share price reflects regulatory policies, drug demand cycles, and product pipeline progress within the pharma sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical export themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s API manufacturing market.